The survival benefit of increasing the number of active drugs for metastatic colorectal cancer: A multicenter retrospective study
Sign Up to like & getrecommendations! Published in 2022 at "Cancer Medicine"
DOI: 10.1002/cam4.4599
Abstract: The development of chemotherapy and treatment strategies for metastatic colorectal cancer (mCRC) have provided patients with significant survival benefits. Currently, molecular targeting agents and late‐line treatment with regorafenib and trifluridine/tipiracil (FTD/TPI) are available. However, the… read more here.
Keywords: benefit increasing; survival benefit; metastatic colorectal; increasing number ... See more keywords